The Other Drug For Avian Flu

Stuckey does say GSK is not spending close to $100 million on expanding production of Relenza. Of this amount, the company recently spent $15 million to boost Relenza output at a plant in Australia. As to GSK’s current capacity, “we don’t provide specific numbers because the number changes as we work on increasing capacity,” Stuckey says. ................
................